Claudio Marcocci

List of Publications by Year
in descending order

103	8,124	94433 37	51608 86
papers	citations	h-index	g-index

109	109	109	6057
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e372-e385.	3.6	23
2	Hypercalcemia due to CYP24A1 mutations: a systematic descriptive review. European Journal of Endocrinology, 2022, 186, 137-149.	3.7	17
3	European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). European Journal of Endocrinology, 2022, 186, R33-R63.	3.7	73
4	Circulating MicroRNAs as Biomarkers of Osteoporosis and Fragility Fractures. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2267-2285.	3.6	10
5	Long-term Efficacy and Safety of Rifampin in the Treatment of a Patient Carrying a CYP24A1 Loss-of-Function Variant. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3159-e3166.	3.6	11
6	Disappearance of Anti-Thyroid Autoantibodies following Thymectomy in Patients with Myasthenia Gravis. European Thyroid Journal, 2021, 10, 237-247.	2.4	7
7	PCB153 reduces apoptosis in primary cultures of murine pituitary cells through the activation of NF-ÎºB mediated by PI3K/Akt. Molecular and Cellular Endocrinology, 2021, 520, 111090.	3.2	8
8	Do the Heterozygous Carriers of a CYP24A1 Mutation Display a Different Biochemical Phenotype Than Wild Types?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 708-717.	3.6	11
9	Concomitant Primary Hyperparathyroidism in Patients with Multiple Myeloma: A Possible Link?. Acta Haematologica, 2021, 144, 302-307.	1.4	4
10	Genetic Profiling of Orbital Fibroblasts from Patients with Gravesâ€™ Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2176-e2190.	3.6	18
11	Gene expression profile in metastatic and non-metastatic parathyroid carcinoma. Endocrine-Related Cancer, 2021, 28, 111-134.	3.1	14
12	Pseudohypoparathyroidism: Focus on Cerebral and Renal Calcifications. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3005-e3020.	3.6	6
13	Statins: A New Hope on the Horizon of Graves Orbitopathy?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2819-e2821.	3.6	4
14	Beneficial effect of low-dose radioiodine ablation for Gravesâ€™ orbitopathy: results of a retrospective study. Journal of Endocrinological Investigation, 2021, 44, 2575-2579.	3.3	4
15	Dietary calcium intake in a cohort of individuals evaluated for low bone mineral density: a multicenter Italian study. Aging Clinical and Experimental Research, 2021, , 1.	2.9	2
16	Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade. Journal of the Endocrine Society, 2021, 5, bvab093.	0.2	3
17	Bone fragility in patients with diabetes mellitus: A consensus statement from the working group of the Italian Diabetes Society (SID), Italian Society of Endocrinology (SIE), Italian Society of Gerontology and Geriatrics (SIGG), Italian Society of Orthopaedics and Traumatology (SIOT). Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1375-1390.	2.6	8
18	Effect of neridronate in osteopenic patients after heart, liver or lung transplant: a multicenter, randomized, double-blind, placebo-controlled study. Panminerva Medica, 2021, 63, 214-223.	0.8	5

#	Article	IF	Citations
19	Do Patients With Atypical Parathyroid Adenoma Need Close Follow-up?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4565-e4579.	3.6	7
20	The 2021 European Group on Gravesâ€™ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Gravesâ€™ orbitopathy. European Journal of Endocrinology, 2021, 185, G43-G67.	3.7	362
21	Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 733-742.	11.4	27
22	Parathyroid Carcinoma and Adenoma Co-existing in One Patient: Case Report and Comparative Proteomic Analysis. Cancer Genomics and Proteomics, 2021, 18, 781-796.	2.0	9
23	Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study. Orphanet Journal of Rare Diseases, 2021, 16, 421.	2.7	5
24	Parathyroid Carcinoma and Ectopic Secretion of Parathyroid hormone. Endocrinology and Metabolism Clinics of North America, 2021, 50, 683-709.	3.2	5
25	Hypercalcemia. Endocrinology and Metabolism Clinics of North America, 2021, 50, xv-xvi.	3.2	0
26	Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 1201-1218.	5.7	74
27	Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 242-251.	3.6	36
28	Circulating Long Non-Coding RNA GAS5 Is Overexpressed in Serum from Osteoporotic Patients and Is Associated with Increased Risk of Bone Fragility. International Journal of Molecular Sciences, 2020, 21, 6930.	4.1	12
29	Antioxidant Therapy in Gravesâ€™ Orbitopathy. Frontiers in Endocrinology, 2020, 11, 608733.	3.5	8
30	Controversies in Vitamin D: A Statement From the Third International Conference. JBMR Plus, 2020, 4, e10417.	2.7	118
31	Twentieth EUGOGO Anniversary Symposium. European Thyroid Journal, 2020, 9, 1-2.	2.4	4
32	Hypomagnesuria is Associated With Nephrolithiasis in Patients With Asymptomatic Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2789-e2795.	3.6	12
33	Late-onset postsurgical hypoparathyroidism following parathyroidectomy for recurrent primary hyperparathyroidism: a case report and literature review. Endocrine, 2020, 69, 402-409.	2.3	0
34	Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1581-1588.	3.6	27
35	A severe inactivating PTH/PTHrP signaling disorder type 2 in a patient carrying a novel large deletion of the GNAS gene: a case report and review of the literature. Endocrine, 2020, 67, 466-472.	2.3	2
36	Teprotumumab for the Treatment of Active Thyroid Eye Disease. New England Journal of Medicine, 2020, 382, 341-352.	27.0	375

#	Article	IF	Citations
37	Selenium in the Treatment of Gravesâ€™ Hyperthyroidism and Eye Disease. Frontiers in Endocrinology, 2020, 11, 608428.	3.5	24
38	Oxidative Stress in Graves Disease and Graves Orbitopathy. European Thyroid Journal, 2020, 9, 40-50.	2.4	22
39	TSH suppressive therapy and bone. Endocrine Connections, 2020, 9, R158-R172.	1.9	20
40	Unmet therapeutic, educational and scientific needs in parathyroid disorders: Consensus Statement from the first European Society of Endocrinology Workshop (PARAT). European Journal of Endocrinology, 2019, 181, P1-P19.	3.7	61
41	A Case of Unilateral Dermopathy Possibly Related to Gravesâ€™ Disease. European Thyroid Journal, 2019, 8, 278-282.	2.4	1
42	Gravesâ€™ Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. European Thyroid Journal, 2019, 8, 192-195.	2.4	49
43	Hereditary Hypercalcemia Caused by a Homozygous Pathogenic Variant in theCYP24A1Gene: A Case Report and Review of the Literature. Case Reports in Endocrinology, 2019, 2019, 1-7.	0.4	17
44	Immune Checkpoint Blockade Antiâ€“PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome. Journal of the Endocrine Society, 2019, 3, 496-503.	0.2	50
45	Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. Endocrine Reviews, 2019, 40, 1109-1151.	20.1	611
46	Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases. Endocrinology, Diabetes and Metabolism Case Reports, 2019, 2019, .	0.5	35
47	Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocrine-Related Cancer, 2019, 26, R441-R464.	3.1	87
48	A patient with MEN1 and endâ€‘stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation. Molecular and Clinical Oncology, 2018, 8, 449-452.	1.0	0
49	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. Calcified Tissue International, 2018, 103, 151-163.	3.1	23
50	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. Endocrine, 2018, 62, 215-233.	2.3	21
51	Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy. JAMA Ophthalmology, 2018, 136, 613.	2.5	52
52	Occurrence of Gravesâ€™ Orbitopathy and Gravesâ€™ Hyperthyroidism after a Trauma to the Eye. European Thyroid Journal, 2018, 7, 51-54.	2.4	2
53	Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 287-298.	11.4	128
54	High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study. Thyroid, 2018, 28, 386-394.	4.5	64

#	Article	IF	Citations
55	A rapid screening of a recurrent CYP24A1 pathogenic variant opens the way to molecular testing for Idiopathic Infantile Hypercalcemia (IIH). Clinica Chimica Acta, 2018, 482, 8-13.	1.1	9
56	Clinical profile of juvenile primary hyperparathyroidism: a prospective study. Endocrine, 2018, 59, 344-352.	2.3	6
57	Non-surgical management of primary hyperparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 821-835.	4.7	19
58	Mechanistic Pathways of Selenium in the Treatment of Gravesâ€™ Disease and Gravesâ€™ Orbitopathy. Hormone and Metabolic Research, 2018, 50, 887-893.	1.5	16
59	Development of an algorithm to predict serum vitamin D levels using a simple questionnaire based on sunlight exposure. Endocrine, 2017, 55, 85-92.	2.3	7
60	Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. Endocrine, 2017, 55, 256-265.	2.3	42
61	Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. Endocrine, 2017, 55, 386-397.	2.3	42
62	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine, 2017, 58, 349-359.	2.3	77
63	Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in gravesâ€™ orbitopathy. Endocrine, 2017, 58, 386-389.	2.3	17
64	Selenium in the Treatment of Thyroid Diseases. European Thyroid Journal, 2017, 6, 113-114.	2.4	9
65	Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. European Journal of Endocrinology, 2017, 177, 127-135.	3.7	26
66	Hypovitaminosis D in patients with heart failure: effects on functional capacity and patientsâ€™ survival. Endocrine, 2017, 58, 574-581.	2.3	23
67	Does Gravesâ€™ Orbitopathy Ever Disappear Answers to an Old Question. European Thyroid Journal, 2017, 6, 263-270.	2.4	16
68	Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Gravesâ€™ Orbitopathy. Thyroid, 2017, 27, 271-278.	4.5	53
69	Natural history of gravesâ€™ orbitopathy after treatment. Endocrine, 2017, 57, 226-233.	2.3	11
70	Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features. PLoS ONE, 2017, 12, e0186485.	2.5	31
71	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. European Thyroid Journal, 2016, 5, 9-26.	2.4	738
72	A 2016 Italian Survey about the Clinical Use of Selenium in Thyroid Disease. European Thyroid Journal, 2016, 5, 164-170.	2.4	41

#	Article	IF	Citations
73	Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. European Journal of Endocrinology, 2016, 175, 443-453.	3.7	29
74	Primary hyperparathyroidism. Nature Reviews Disease Primers, 2016, 2, 16033.	30.5	180
75	Divergent Effects of Dioxin- or Non-Dioxin-Like Polychlorinated Biphenyls on the Apoptosis of Primary Cell Culture from the Mouse Pituitary Gland. PLoS ONE, 2016, 11, e0146729.	2.5	18
76	A nonfunctioning parathyroid carcinoma misdiagnosed as a follicular thyroid nodule. World Journal of Surgical Oncology, 2015, 13, 270.	1.9	18
77	Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4. Endocrine Connections, 2015, 4, 1-8.	1.9	44
78	Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study. European Journal of Endocrinology, 2015, 172, 269-276.	3.7	48
79	Role of the Underlying Thyroid Disease on the Phenotype of Graves' Orbitopathy in a Tertiary Referral Center. Thyroid, 2015, 25, 347-351.	4.5	38
80	Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy. Thyroid, 2015, 25, 846-850.	4.5	32
81	Epidemiology, pathogenesis of primary hyperparathyroidism: Current data. Annales D'Endocrinologie, 2015, 76, 113-115.	1.4	18
82	PREGO (presentation of Gravesâ€™ orbitopathy) study: changes in referral patterns to European Group On Gravesâ€™ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. British Journal of Ophthalmology, 2015, 99, 1531-1535.	3.9	92
83	Diagnosis and classification of Graves' disease. Autoimmunity Reviews, 2014, 13, 398-402.	5.8	205
84	Medical Management of Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3607-3618.	3.6	179
85	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3561-3569.	3.6	1,277
86	Enalapril Reduces Proliferation and Hyaluronic Acid Release in Orbital Fibroblasts. Thyroid, 2013, 23, 92-96.	4.5	21
87	CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocrine Connections, 2013, 2, 186-195.	1.9	76
88	Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. European Journal of Endocrinology, 2012, 166, 247-253.	3.7	112
89	Bone disease in primary hyperparathyrodism. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 357-368.	2.7	43
90	Oxidative Stress in GravesÂ' Disease. European Thyroid Journal, 2012, 1, 80-87.	2.4	74

#	Article	IF	Citations
91	Treatment options for Graves' orbitopathy. Expert Opinion on Pharmacotherapy, 2012, 13, 795-806.	1.8	13
92	Treatment of mild, moderate-to-severe and very severe Gravesâ€™ orbitopathy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 325-337.	4.7	66
93	Primary Hyperparathyroidism. New England Journal of Medicine, 2011, 365, 2389-2397.	27.0	312
94	Selenium and the Course of Mild Graves' Orbitopathy. New England Journal of Medicine, 2011, 364, 1920-1931.	27.0	503
95	Cinacalcet Reduces Serum Calcium Concentrations in Patients with Intractable Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2766-2772.	3.6	134
96	Parathyroid Carcinoma. Journal of Bone and Mineral Research, 2008, 23, 1869-1880.	2.8	243
97	HRPT2gene analysis and the diagnosis of parathyroid carcinoma. Expert Review of Endocrinology and Metabolism, 2008, 3, 377-389.	2.4	4
98	A treatment strategy for Graves' orbitopathy. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 430-436.	2.8	20
99	Genetic Analyses of theHRPT2Gene in Primary Hyperparathyroidism: Germline and Somatic Mutations in Familial and Sporadic Parathyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5583-5591.	3.6	234
100	Novel aspects of immunosuppressive and radiotherapy management of Gravesâ€™ ophthalmopathy. Journal of Endocrinological Investigation, 2004, 27, 272-280.	3.3	21
101	Long-Term Safety of Orbital Radiotherapy for Gravesâ€™ Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3561-3566.	3.6	105
102	Current Medical Management of Graves Ophthalmopathy. Ophthalmic Plastic and Reconstructive Surgery, 2002, 18, 402-408.	0.8	12
103	Genetic analysis of the MEN1 gene and HPRT2 locus in two Italian kindreds with familial isolated hyperparathyroidism. Clinical Endocrinology, 2002, 56, 457-464.	2.4	32